CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) Form 8-K — Aug 5, 2026
Charles River Laboratories reported second-quarter 2026 revenue of $1.00 billion, down 2.7% year over year, with non-GAAP EPS of $3.02 and a GAAP loss per share of $(0.03) driven by a $63.7 million loss on the CDMO and Cell Solutions divestitures. The company raised its 2026 outlook, lifting organic revenue guidance by 150 basis points to 0.0%-1.0% and non-GAAP EPS guidance by $0.25 at the midpoint to $11.15-$11.45, citing improving DSA demand — including the highest net book-to-bill in nearly four years — and better-than-expected Manufacturing performance. GAAP EPS guidance was lowered to $3.05-$3.35 due to the divestiture losses.
Key figures
- Eps
- GAAP diluted $(0.03); non-GAAP diluted $3.02
- Revenue
- 1004078000
- Guidance
- FY2026 reported revenue growth (3.5)%-(2.5)% (prior (5.5)%-(4.0)%); organic revenue growth 0.0%-1.0% (prior (1.5)%-(0.5)%); non-GAAP EPS $11.15-$11.45 (prior $10.80-$11.30); GAAP EPS lowered to $3.05-$3.35 (prior $5.35-$5.85) due to divestiture losses
- Total Debt
- 2619985000
- Revenue Yoy
- -2.7%
- Total Assets
- 7532145000
- Cash Position
- 192025000
- Shares Outstanding
- 47728000
- Q2 buyback
- $100.0 million (0.6 million shares at average $174 per share)
- Ytd buyback
- $300.0 million (1.7 million shares)
- Book to bill
- highest net book-to-bill in nearly four years
- Non gaap eps yoy
- -3.2%
- Divestiture loss q2
- $63.7 million ($1.40 per share)
- Dsa segment revenue
- 606500000
- Rms segment revenue
- 209500000
- Non gaap net income q2
- 146200000
- Gaap operating margin q2
- 11.9%
- Organic revenue growth q2
- 0.1%
- Non gaap operating margin q2
- 20.5%
- Manufacturing segment revenue
- 188100000
- Remaining buyback authorization
- $700.0 million under $1.0 billion authorization
- Non gaap operating margin yoy prior
- 22.1%
Price after filing
Close on the filing date to close N calendar days later (from $234.12). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.